The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections (uUTIs) in adult females ...

A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The medication, gepotidacin, targets E. coli bacteria, which is responsible for ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...

GSK recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite these ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...